Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site [Yahoo! Finance]
Kiromic BioPharma, Inc. (KRBP)
Company Research
Source: Yahoo! Finance
has been activated as the fourth clinical trial site in the Deltacel-01 Phase 1 trial evaluating Deltacel ™ (KB-GDT-01), Kiromic's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC). UPMC is a world-renowned healthcare system that employs some of the nation's top clinicians and medical researchers. UPMC Hillman Cancer Center is Western Pennsylvania's only National Cancer Institute-designated Comprehensive Cancer Center. The lead principal investigator for Deltacel-01, Jason J. Luke, MD, FACP, will also serve as principal investigator at the UPMC site. Dr. Luke is Associate Professor of Medicine at the University of Pittsburgh and UPMC Hillman Cancer Center, where he is Associate Director for Clinical Research and Director of the Immunotherapy and Drug Development Center. "We're delighted to have Dr. Jason Luke and UPMC participating in the conduct of research of our potentially transformative therap
Show less
Read more
Impact Snapshot
Event Time:
KRBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRBP alerts
High impacting Kiromic BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
KRBP
News
- Kiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical Trial [Yahoo! Finance]Yahoo! Finance
- Kiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical TrialBusiness Wire
- Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical TrialBusiness Wire
- Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial SiteBusiness Wire
- Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients [Yahoo! Finance]Yahoo! Finance
KRBP
Sec Filings
- 6/13/24 - Form 4
- 6/13/24 - Form 4
- 6/12/24 - Form 4
- KRBP's page on the SEC website